Palivizumab

Type: Product
Name: Palivizumab
First reported 2 hours ago - Updated 1 hour ago - 1 reports

AbbVie Q3 Profit Falls, But Sales Up; Lifts Full-year Outlook

Research-based biopharmaceutical company AbbVie Inc. (ABBV: Quote) Friday reported a fall in the third-quarter profit, reflecting higher expenses. Sales, however, grew on continued strength of its blockbuster rheumatoid arthritis drug Humira, and several ... [Published RTTNews.com - 2 hours ago]
First reported 4 hours ago - Updated 4 hours ago - 1 reports

AbbVie Reports Third-Quarter 2014 Financial Results

- Reports Third-Quarter Adjusted EPS of $0.89, Up 8.5 Percent and Well Above the Previous Guidance Range of $0.77 to $0.79; Reports GAAP EPS of $0.31- Significantly Raises 2014 Adjusted EPS Guidance Range to $3.25 to $3.27 from $3.06 to $3.16 (GAAP EPS ... [Published Scottrade - 4 hours ago]
First reported Oct 27 2014 - Updated Oct 27 2014 - 1 reports

China Independent Clinical Laboratory Market Size 2014, Industry Analysis, Shares, Growth, Trends and Forecast 2017: MarketResearchReports.Biz

MarketResearchReports.Biz include new market research report" China Independent Clinical Laboratory Industry Report, 2014-2017" to its huge collection of research reports. Browse All Biotechnology Market Research Reports at The independent clinical laboratory ... [Published PRWeb - Oct 27 2014]
First reported Oct 21 2014 - Updated Oct 21 2014 - 1 reports

Novavax RSV F-protein nanoparticle vaccine induces antigenic site II antibodies

GAITHERSBURG, Md.—Novavax, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that its RSV F-protein nanoparticle vaccine candidate ... [Published Drug Discovery News - Oct 21 2014]
First reported Oct 20 2014 - Updated Oct 21 2014 - 2 reports

Market Overview:Global And China Monoclonal Antibody Industry Report, 2014-2019

Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biotech drugs with the fastest CAGR in recent years.To ... [Published MyNewsDesk - Oct 21 2014]
First reported Oct 21 2014 - Updated Oct 21 2014 - 1 reports

Stock Update (NYSE:ABBV): AbbVie says $55 billion acquisition of Shire officially dead

[Reuters - UK Focus] – AbbVie, which last week said its board of directors had withdrawn its recommendation to proceed with the Shire purchase, blamed the unraveling on last month’s rules changes by the U.S. Treasury Department aimed at curtailing a wave ... [Published Jutia Group - Oct 21 2014]
First reported Oct 15 2014 - Updated Oct 16 2014 - 1 reports

Novavax Study Published in Vaccine: RSV F-Protein Nanoparticle Vaccine Induces Antigenic Site II Antibodies

• Vaccinated Animals Generated a Broad Spectrum of Protective Antibodies• Vaccine Induces Antibodies that are at Least as Protective as PalivizumabPalivizumab Competing Antibody Response from Vaccine Protects Against BothGaithersburg, MD - October 15, ... [Published Noodls - Oct 15 2014]
First reported Oct 01 2014 - Updated Oct 01 2014 - 1 reports

J&J bets $1.75 billion on virology

Johnson & Johnson has signed a deal to acquire Alios BioPharma, a privately-held company focussed on developing therapies for viral diseases, for around $1.75 billion in cash.The acquisition will include Alios BioPharma’s portfolio of potential therapeutics ... [Published Pharmafocus - Oct 01 2014]
First reported Sep 30 2014 - Updated Oct 01 2014 - 2 reports

J&J's Alios Buyout Bodes Interesting Times For Gilead

The drama continued for big biotech Gilead Sciences Tuesday, as Johnson & Johnson moved into its viral-disease turf on two fronts with an acquisition.Johnson & Johnson (NYSE: JNJ ) disclosed that it's buying privately held Alios BioPharma for $1.75 billion ... [Published Investor's Business Daily - Sep 30 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 2 reports

UPDATE 2-Johnson & Johnson to buy private drug developer for $1.75 bln

(Adds J&J comment, deal advisers, updates share price)By Vidya L Nathan(Reuters) - Johnson & Johnson agreed to pay$1.75 billion in cash to buy privately held Alios BioPharma Inc,which is developing a drug for a common respiratory viralinfection in children ... [Published Reuters - Sep 30 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

ICAAC Presentation: Immunization of Pregnant Baboons With the RSV F Nanoparticle Vaccine Protects Infant Baboons

* Immunization of pregnant baboons generates anti-F IgG antibodies that are transferred from mothers to their infants * When challenged with RSV, infant baboons born to immunized mothers show equivalent protection to infant baboons receiving palivizumab ... [Published PR inside - Sep 23 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Pediatricians clash with maker of drug for babies

Leading pediatrician's group says prescription Synagis should not be given to so many kids; drugmaker fires back ... [Published Latest Econwatch Headlines - CBS News - Jul 28 2014]
Entities: Drugs, Palivizumab

Quotes

"Our third-quarter results reflect the strong performance of our business with double-digit growth from HUMIRA and several other key brands. Our underlying business grew nearly 14 percent in the quarter excluding lipids" said Richard Gonzalez, chairman and chief executive, AbbVie
...underlying business grew nearly 14 percent in the quarter excluding lipids," said Richard A Gonzalez, chairman and chief executive officer, AbbVie. "We exceeded our outlook for the quarter and have significantly raised our original 2014 guidance. In the fourth quarter, we look forward to the U S approval of our interferon-free HCV combination, which will further accelerate sales and earnings growth in 2015 and beyond."
Daniel J O'Connor, President and CEO of Advaxis, remarked, "Though we recognize that the data is preliminary, it suggests a positive therapeutic response in the treated patients that warrants further investigation. Our strategy is to provide an immunotherapeutic treatment option to patients with HPV-associated anal, cervical and head & neck cancer - each of which Advaxis has obtained orphan drug status."
"So while the promise of Alios's RSV candidate can partly explain this move, its much earlier stage hep C pipeline surely played a big role.”"

More Content

All (24) | News (22) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
AbbVie Q3 Earnings Top on Humira Sales, Boosts ... [Published Yahoo! Finance - 2 hours ago]
AbbVie Q3 Profit Falls, But Sales Up; Lifts Ful... [Published RTTNews.com - 2 hours ago]
AbbVie Reports Third-Quarter 2014 Financial Res... [Published Scottrade - 4 hours ago]
China Independent Clinical Laboratory Market Si... [Published PRWeb - Oct 27 2014]
Novavax RSV F-protein nanoparticle vaccine indu... [Published Drug Discovery News - Oct 21 2014]
Market Overview:Global And China Monoclonal Ant... [Published MyNewsDesk - Oct 21 2014]
Stock Update (NYSE:ABBV): AbbVie says $55 billi... [Published Jutia Group - Oct 21 2014]
Global monoclonal antibody market size exceeded... [Published MyNewsDesk - Oct 20 2014]
TherapeuticsMD Announces Presentation Of Positi... [Published BioMedReports - Oct 16 2014]
Novavax Study Published in Vaccine: RSV F-Prote... [Published Noodls - Oct 15 2014]
Novavax Study Published in Vaccine: RSV F-Prote... [Published GlobeNewswire: Advertising News - Oct 15 2014]
Johnson & Johnson's Growth Potential Is Stronge... [Published Seeking Alpha - Oct 05 2014]
The preemies next door` [Published Pittsburgh Post-Gazette - Oct 05 2014]
J&J Buys Alios BioPharma, Acquires Antiviral Th... [Published Bioresearch Online - Oct 02 2014]
J&J bets $1.75 billion on virology [Published Pharmafocus - Oct 01 2014]
J&J's Alios Buyout Bodes Interesting Times For ... [Published Investor's Business Daily - Sep 30 2014]
Johnson & Johnson Bets $1.75 Billion On Alios Buy [Published Yahoo! Finance - Sep 30 2014]
UPDATE 2-Johnson & Johnson to buy private drug ... [Published Reuters - Sep 30 2014]
UPDATE 1-Johnson & Johnson to buy private drug ... [Published Reuters UK - Sep 30 2014]
A Pediatrician’s Guide to Caring for the Comple... [Published Orthopedics Today - Sep 26 2014]
ICAAC Presentation: Immunization of Pregnant Ba... [Published PR inside - Sep 23 2014]
Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie D... [Published Jutia Group - Sep 22 2014]
Pediatricians clash with maker of drug for babies [Published Latest Econwatch Headlines - CBS News - Jul 28 2014]
Annual Financial Report [Published TrustNet - Mar 20 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Pediatricians clash with maker of drug for babies [Published Latest Econwatch Headlines - CBS News - Jul 28 2014]
Leading pediatrician's group says prescription Synagis should not be given to so many kids; drugmaker fires back ...
1

Press Releases

sort by: Date | Relevance
Novavax Study Published in Vaccine: RSV F-Prote... [Published GlobeNewswire: Advertising News - Oct 15 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.